Reuters:
LifeVantage Corporation has been granted a third patent for its flagship product Protandim® from the United States Patent and Trademark Office.
Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim`s effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein. C-reactive protein is widely considered by doctors and researchers as an indicator of the amount of inflammation present in the body. Elevated basal levels of C-reactive protein are considered risk factors for diabetes, hypertension, and cardiovascular disease. Thepatent, “Methods for Enhancing Antioxidant Enzyme Activity and Reducing C-Reactive Protein Levels,” was issued on August 25, 2009.
Dr. Joe McCord, one of the foremost authorities on the body`s antioxidant defense system and the co-discoverer of the important antioxidant enzyme superoxide dismutase or SOD, said, “This patent further underscores the unique and powerful actions of Protandim® as a tool against not only oxidative stress, but also inflammation. Chronic, low-level inflammation is now known to be associated with many of the major diseases we face as we age, including atherosclerosis, diabetes, obesity, and neurodegenerative diseases.”
David W. Brown, LifeVantage President and CEO commented, “The issuance of a third patent for Protandim® builds upon our previous two patents and further separates LifeVantage and Protandim® from other dietary supplements. It is difficult to receive a patent for a dietary supplement. Protandim® is uniquely and solidly based upon sound and proven science and the issuance of this third patent marks a historic day for LifeVantage, and sets an unparalleled standard in the dietary supplement industry.”
Logo from LifeVantage